EPIX reaches agreement with FDA over contrast agent

TriMed Staff | | Health Imaging | Cardiac Imaging
 
Contrast enhanced thrombi image. Source: Epix Pharmaceuticals provided image to Nature. 
EPIX Pharmaceuticals reached agreement Thursday with the FDA on its proposal for the re-read of images that utilize its blood pool MR angiographic (MRA) contrast agent, Vasovist (gadofosveset trisodium). 

The Lexington, Mass.-based company said it has initiated the re-read of images obtained in prior Phase 3 studies.

EPIX said it received an action letter from the FDA confirming that the jointly agreed-upon protocol design and statistical analysis plan adequately address the objectives necessary to support the resubmission of the New Drug Application for Vasovist, which has been approved for marketing in 33 countries outside of the United States.

TriMed Staff

Related Content

Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures
New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup